Examining the effectiveness and duration of adjuvanted vs. non‐adjuvanted influenza vaccines in protecting older adults against symptomatic SARS‐CoV‐2 infection
Abstract Annual influenza vaccination is one of the main public health measures able to drastically reduce the burden of this infectious disease. Some evidence suggests ‘trained immunity’ triggered by influenza vaccine might reduce the risk of SARS‐CoV‐2 infection. Adjuvanted influenza vaccines are known to induce a broader cross‐reactive immunity. No studies investigated the effect of adjuvanted vs. non‐adjuvanted influenza vaccines on the risk of symptomatic SARS‐CoV‐2 infection. A case–control analysis nested in a cohort of subjects aged ≥65 years and immunized with adjuvanted or non‐adjuvanted influenza vaccines was conducted. Although no statistically significant (OR = 0.87; P = .082) difference between the two vaccine types was observed for the 9‐month follow‐up period, a 17% (OR = 0.83; P = .042) reduction in the odds of COVID‐19 was observed for adjuvanted vaccines with a 6‐month follow‐up. Further evidence is needed, but these results might have implications given the complexity of the upcoming winter seasons, in which the co‐occurrence of influenza, SARS‐CoV‐2 and other respiratory infections (e.g., syncytial virus) might be unpredictable..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:90 |
|---|---|
| Enthalten in: |
British Journal of Clinical Pharmacology - 90(2024), 2, Seite 600-605 |
| Beteiligte Personen: |
Lapi, Francesco [VerfasserIn] |
|---|
| Anmerkungen: |
© 2024 The British Pharmacological Society |
|---|
| Umfang: |
6 |
|---|
| doi: |
10.1111/bcp.15940 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY017261139 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY017261139 | ||
| 003 | DE-627 | ||
| 005 | 20240422162455.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240422s2024 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/bcp.15940 |2 doi | |
| 028 | 5 | 2 | |a 2024-04-22_BCP_2024_90_2.zip.xml |
| 035 | |a (DE-627)WLY017261139 | ||
| 035 | |a (WILEY)BCP15940 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Lapi, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Examining the effectiveness and duration of adjuvanted vs. non‐adjuvanted influenza vaccines in protecting older adults against symptomatic SARS‐CoV‐2 infection |
| 264 | 1 | |c 2024 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2024 The British Pharmacological Society | ||
| 520 | |a Abstract Annual influenza vaccination is one of the main public health measures able to drastically reduce the burden of this infectious disease. Some evidence suggests ‘trained immunity’ triggered by influenza vaccine might reduce the risk of SARS‐CoV‐2 infection. Adjuvanted influenza vaccines are known to induce a broader cross‐reactive immunity. No studies investigated the effect of adjuvanted vs. non‐adjuvanted influenza vaccines on the risk of symptomatic SARS‐CoV‐2 infection. A case–control analysis nested in a cohort of subjects aged ≥65 years and immunized with adjuvanted or non‐adjuvanted influenza vaccines was conducted. Although no statistically significant (OR = 0.87; P = .082) difference between the two vaccine types was observed for the 9‐month follow‐up period, a 17% (OR = 0.83; P = .042) reduction in the odds of COVID‐19 was observed for adjuvanted vaccines with a 6‐month follow‐up. Further evidence is needed, but these results might have implications given the complexity of the upcoming winter seasons, in which the co‐occurrence of influenza, SARS‐CoV‐2 and other respiratory infections (e.g., syncytial virus) might be unpredictable. | ||
| 700 | 1 | |a Domnich, Alexander |4 aut | |
| 700 | 1 | |a Marconi, Ettore |4 aut | |
| 700 | 1 | |a Rossi, Alessandro |4 aut | |
| 700 | 1 | |a Grattagliano, Ignazio |4 aut | |
| 700 | 1 | |a Cricelli, Claudio |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British Journal of Clinical Pharmacology |g 90(2024), 2, Seite 600-605 |w (DE-627)WLY00261751X |x 13652125 |7 nnns |
| 773 | 1 | 8 | |g volume:90 |g year:2024 |g number:2 |g pages:600-605 |g extent:6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 90 |j 2024 |e 2 |h 600-605 |g 6 | ||